US company acquires Pharmanet subsidiary
12 December, 2005 by Ruth BeranMolecular Pharmacology, a US company which recently backdoor-listed on Nasdaq through former exploration mining firm Blue Hawk Ventures, has acquired Perth-based Pharmanet Group's (ASX:PNO) wholly-owned subsidiary Molecular Pharmacology (MPL Australia).
Peptech joins in Domantis fundraising
12 December, 2005 by Helen SchullerSydney-based Peptech (ASX:PTD) has invested more than AUD$10 million in Domantis, as part of a £17 million (AUD$39.5 million) capital raising by the UK drug development firm, which attracted two new significant shareholders.
CSIRO, PolyNovo extend orthopaedic collaboration
08 December, 2005 by Graeme O'NeillPolyNovo Biomaterials and the CSIRO have shaken hands on an agreement to extend their collaboration on a radical new method of repairing damaged cartilage in the knees and joints, using the CSIRO-developed biopolymer NovoSorb.
Transgenic livestock, by half measures
06 December, 2005 by Graeme O'NeillManipulating the genome before fertilisation could prove more successful that current technique used in animal transgenesis, Graeme O'Neill reports.
Alchemia and TetraQ to collaborate on pain treatments
05 December, 2005 by Helen SchullerBrisbane biopharma Alchemia (ASX:ACL) will commence a collaborative research project next year with the University of Queensland through its preclinical service provider, TetraQ to develop a new generation of opioid-based painkillers to treat severe pain.
More delays in GTG-Applera case
05 December, 2005 by Graeme O'NeillTwo deadlines have come and gone, and a third expires today for Melbourne gene-testing company Genetic Technologies (ASX:GTG; NASDAQ:GENE) and US firm Applera, who were due to announce a resolution of their licensing dispute in California today.
BioDiem to trial blindness treatment
01 December, 2005 by Helen SchullerMelbourne-based biopharma BioDiem (ASX:BDM) has received regulatory approval to commence a phase I/II clinical trial for its peptide BDM-E in patients with diabetic macula oedema, a leading cause of blindness.
In brief: C3, SSH, Axon
30 November, 2005 by Ruth BeranClinical Cell Culture's (ASX:CCE) co-founder Prof Fiona Wood will step down from the company's board on December 31. She will remain as a consultant, an R&D partner through her research vehicle the McComb Foundation, and a substantial shareholder.
Visiomed aims to raise $1.6m
30 November, 2005 by Ruth BeranPerth-based biomedical devices developer Visiomed Group (ASX:VSG) is aiming to raise AUD$1.6 million after costs through a placement of up to 90 million shares at $0.02 each.
Ambri on the hunt for M&A targets
30 November, 2005 by Ruth BeranSydney-based Ambri (ASX:ABI) is looking to merge with another medical diagnostics company with products that are closer to market.
The designer dairy cow
30 November, 2005 by Graeme O'NeillComparative genomics is helping speed up the identification of genes for desirable production traits in livestock, Graeme O'Neill reports.
Plants, proteins and proteomics
29 November, 2005 by Susan WilliamsonProfiling proteins is a challenging undertaking. But new research is providing new insights into protein structure and function, reports Susan Williamson.
Positive results for Peplin phase IIa 'sun spot' trial
28 November, 2005 by Helen SchullerPeplin (ASX:PEP) has reported positive results from its phase IIa clinical trial of its proprietary drug PEP005 Topical in actinic keratosis (AK), also known as solar keratosis, a skin condition which can develop into skin cancer.
US Army to participate in Neuren phase III trials
24 November, 2005 by Helen SchullerAuckland biopharma Neuren Pharmaceuticals (ASX:NEU) has executed a memorandum of understanding (MOU) with the Henry M. Jackson Foundation for the Advancement of Military Medicine for inclusion of US Army hospital sites in Neuren's phase III trial of its lead drug Glypromate.
Probiomics to commence flu vaccine trial
24 November, 2005 by Ruth BeranProbiomics' (ASX:PCC) shares increased by more than 25 per cent yesterday on news that the company will undertake a clinical trial to examine the ability of its proprietary probiotic strain PCC to boost the immune response to a vaccine for influenza.
